Praxis Precision Medicines (PRAX) Equity Average (2019 - 2026)

Praxis Precision Medicines' Equity Average history runs 8 years deep, the most recent figure standing at $1.1 billion for Q1 2026.

• In Q1 2026, Equity Average rose 158.64% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $1.1 billion (up 158.64% YoY), while the FY2025 annual figure was $661.8 million, up 156.95% from the prior year.
• Equity Average was $1.1 billion for Q1 2026 at Praxis Precision Medicines, up from $610.8 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $1.1 billion in Q1 2026 to a low of $70.3 million in Q1 2023.
• Historically, Equity Average has averaged $306.5 million across 5 years, with a median of $220.9 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Equity Average plunged 68.18% in 2023, then surged 429.4% in 2024.
• A 5-year view of Equity Average shows it stood at $90.6 million in 2022, then fell by 13.71% to $78.2 million in 2023, then soared by 429.4% to $414.1 million in 2024, then surged by 47.52% to $610.8 million in 2025, then jumped by 87.3% to $1.1 billion in 2026.
• The last three Equity Average figures came in at $1.1 billion (Q1 2026), $610.8 million (Q4 2025), and $373.9 million (Q3 2025), per Business Quant data.